COVID-19 Effects on Geriatric Population and Failures of Aminoquinoline Therapy : Compilation of Studies from EU, USA, and China; Safety and Efficacy of Vaccines in the Prevention and Treatment of COVID-19
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
BACKGROUND: Mortality of the older adult population suffering from COVID-19 has been increasing at an alarming rate, and people older than 76 years of age reported 18% mortality. Mainly, the EU and USA exhibited a greater fatality rate due to lack of selective immunization and anti-SARS Co-V-2 therapeutics. Very limited reports are available to delineate the impact of COVID-19 on the geriatric population and the failures of aminoquinoline therapy.
METHODS: We performed a substantial literature review in the PubMed/Medline databases to extract the information pertaining to the COVID-19 impact on the geriatric population and recent failures of aminoquinoline therapy in COVID-19 patients of EU, China, USA and the requirement of vaccination.
RESULTS AND DISCUSSIONS: Both parental strains and mutant variants of SARS Co-V-2 can induce severe respiratory complications, multiorgan failure, and clotting abnormalities in older adults due to low immunocompetence. Aminoquinoline derivatives, such as chloroquine (CQ) and hydroxychloroquine (HCQ), are preferred primarily for COVID-19 treatment, but several controversies are being reported for its usage worldwide. In this review, we have provided the effects of COVID-19 on the geriatric population of EU and an overview of the mechanism of action of aminoquinolines. Furthermore, CQ and HCQ are not the preferred choice of drugs if the COVID-19 patients already have existing co-morbid conditions viz., diabetes mellitus and hypertension.
CONCLUSION: A new advent of COVID-19 vaccines, such as nucleic acid-based (DNA/mRNA) vaccines, protein subunit vaccines, viral vector vaccines, and inactivated vaccines, have been developed for treating SARS-CoV-2 infection after the failure of aminoquinoline therapy in EU, China, and USA patients. However, some of the vaccines are yet to be examined against mutant strains of SARS CoV-2 that originated in the UK, Nigeria, South Africa, Brazil, and India.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
|---|---|
| Enthalten in: |
Current medicinal chemistry - 29(2022), 20 vom: 03., Seite 3601-3621 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Beeraka, Narasimha M [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 26.05.2022 Date Revised 07.12.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2174/0929867329666220301113146 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM337636397 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM337636397 | ||
| 003 | DE-627 | ||
| 005 | 20231225234853.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/0929867329666220301113146 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1125.xml |
| 035 | |a (DE-627)NLM337636397 | ||
| 035 | |a (NLM)35232337 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Beeraka, Narasimha M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a COVID-19 Effects on Geriatric Population and Failures of Aminoquinoline Therapy |b Compilation of Studies from EU, USA, and China; Safety and Efficacy of Vaccines in the Prevention and Treatment of COVID-19 |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.05.2022 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a BACKGROUND: Mortality of the older adult population suffering from COVID-19 has been increasing at an alarming rate, and people older than 76 years of age reported 18% mortality. Mainly, the EU and USA exhibited a greater fatality rate due to lack of selective immunization and anti-SARS Co-V-2 therapeutics. Very limited reports are available to delineate the impact of COVID-19 on the geriatric population and the failures of aminoquinoline therapy | ||
| 520 | |a METHODS: We performed a substantial literature review in the PubMed/Medline databases to extract the information pertaining to the COVID-19 impact on the geriatric population and recent failures of aminoquinoline therapy in COVID-19 patients of EU, China, USA and the requirement of vaccination | ||
| 520 | |a RESULTS AND DISCUSSIONS: Both parental strains and mutant variants of SARS Co-V-2 can induce severe respiratory complications, multiorgan failure, and clotting abnormalities in older adults due to low immunocompetence. Aminoquinoline derivatives, such as chloroquine (CQ) and hydroxychloroquine (HCQ), are preferred primarily for COVID-19 treatment, but several controversies are being reported for its usage worldwide. In this review, we have provided the effects of COVID-19 on the geriatric population of EU and an overview of the mechanism of action of aminoquinolines. Furthermore, CQ and HCQ are not the preferred choice of drugs if the COVID-19 patients already have existing co-morbid conditions viz., diabetes mellitus and hypertension | ||
| 520 | |a CONCLUSION: A new advent of COVID-19 vaccines, such as nucleic acid-based (DNA/mRNA) vaccines, protein subunit vaccines, viral vector vaccines, and inactivated vaccines, have been developed for treating SARS-CoV-2 infection after the failure of aminoquinoline therapy in EU, China, and USA patients. However, some of the vaccines are yet to be examined against mutant strains of SARS CoV-2 that originated in the UK, Nigeria, South Africa, Brazil, and India | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a CQ | |
| 650 | 4 | |a Geriatric population | |
| 650 | 4 | |a HCQ | |
| 650 | 4 | |a SARS CoV-2 | |
| 650 | 4 | |a aminoquinoline therapy | |
| 650 | 4 | |a clinical studies | |
| 650 | 4 | |a pharmacology | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a Vaccines |2 NLM | |
| 650 | 7 | |a Hydroxychloroquine |2 NLM | |
| 650 | 7 | |a 4QWG6N8QKH |2 NLM | |
| 650 | 7 | |a Chloroquine |2 NLM | |
| 650 | 7 | |a 886U3H6UFF |2 NLM | |
| 700 | 1 | |a Tulimilli, SubbaRao V |e verfasserin |4 aut | |
| 700 | 1 | |a Greeshma, Mandya V |e verfasserin |4 aut | |
| 700 | 1 | |a Dallavalasa, Siva |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Yaowen |e verfasserin |4 aut | |
| 700 | 1 | |a Xiao, Wenjing |e verfasserin |4 aut | |
| 700 | 1 | |a Fan, Ruitai |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Di |e verfasserin |4 aut | |
| 700 | 1 | |a Bettadapura, Anjali D S |e verfasserin |4 aut | |
| 700 | 1 | |a Nataraj, Suma M |e verfasserin |4 aut | |
| 700 | 1 | |a Madhunapantula, SubbaRao V |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Junqi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current medicinal chemistry |d 1997 |g 29(2022), 20 vom: 03., Seite 3601-3621 |w (DE-627)NLM093833857 |x 1875-533X |7 nnns |
| 773 | 1 | 8 | |g volume:29 |g year:2022 |g number:20 |g day:03 |g pages:3601-3621 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/0929867329666220301113146 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 29 |j 2022 |e 20 |b 03 |h 3601-3621 | ||